Posted: Tuesday, April 19, 2022
The gene DLGAP5 appears to be associated with improved overall survival in patients with lung squamous cell carcinoma and worse overall survival in patients with lung adenocarcinoma. In addition, Sudha Mirsa, MD, of Saint Joseph Hospital, Chicago, and colleagues observed that the protein-coding gene WDHD1 may prove to be a surrogate for the development of diagnostic and therapeutic markers for patients with these types of lung cancer. These study findings were presented at the 2022 National Comprehensive Cancer Network (NCCN) Annual Conference (Abstract BIO22-028) and published in JNCCN–Journal of the National Comprehensive Cancer Network.
The investigators analyzed data from GSE10245 and GSE31552 data sets using a GEO2r online tool. Differentially upregulated genes were identified between lung adenocarcinoma and lung squamous cell carcinoma tissue samples. An online Venn diagram software program identified overlapping differentially upregulated genes between these two types of tissue samples.
The study identified 75 lung adenocarcinoma and 43 lung squamous cell carcinoma samples in the GSE10245 and GSE31552 data sets, which contained 1,024 and 189 differentially upregulated genes, respectively. Of the 150 commonly upregulated differentially upregulated genes evaluated with protein-protein interactions (PPI) network, it revealed 94 nodes and 629 edges with significant PPI enrichment. Gene oncology analysis revealed differentially upregulated genes rich in mitotic nuclear division for biologic pathway, microtubule cytoskeleton for cellular component, and protein serine/threonine kinase activity for molecular function.
The final list of genes included BIRC5, NUF2, ASPM, BUB1B, TTK, RAD51AP1, DLGAP5, NEK2, KIF11, PTTG1, CDC6, MELK, TOP2A, KIF23, CENPF, TPX2, KIF4A, CEP55, ECT2, and CDC45. All the genes except BIRC5 were associated with reduced overall survival in patients with lung adenocarcinoma. DLGAP5 was associated with improved overall survival in patients with lung squamous cell carcinoma but was associated with worse survival in patients with lung adenocarcinoma. WDHD1 was identified to have increased co-expression.
Disclosure: The study authors reported no conflicts of interest.